MVIR B Stock Overview
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally.
Medivir AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr7.63|
|52 Week High||kr11.84|
|52 Week Low||kr7.00|
|1 Month Change||-1.29%|
|3 Month Change||-1.29%|
|1 Year Change||-22.93%|
|3 Year Change||-65.63%|
|5 Year Change||-89.02%|
|Change since IPO||-94.26%|
Recent News & Updates
|MVIR B||SE Biotechs||SE Market|
Return vs Industry: MVIR B exceeded the Swedish Biotechs industry which returned -40% over the past year.
Return vs Market: MVIR B exceeded the Swedish Market which returned -28.2% over the past year.
|MVIR B volatility|
|MVIR B Average Weekly Movement||2.9%|
|Biotechs Industry Average Movement||8.0%|
|Market Average Movement||7.0%|
|10% most volatile stocks in SE Market||11.6%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: MVIR B is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: MVIR B's weekly volatility (3%) has been stable over the past year.
About the Company
Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma.
Medivir AB (publ) Fundamentals Summary
|MVIR B fundamental statistics|
Is MVIR B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MVIR B income statement (TTM)|
|Cost of Revenue||kr83.58m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 10, 2022
|Earnings per share (EPS)||-1.68|
|Net Profit Margin||-607.54%|
How did MVIR B perform over the long term?See historical performance and comparison